January 23, 2017 / 12:35 PM / in 8 months

BRIEF-Aptose prioritizes development of CG'806 first-in class FLT3/BTK Inhibitor

Jan 23 (Reuters) - Aptose Biosciences Inc

* Will prioritize resources toward development of CG‘806 for patients with FLT3-driven acute myeloid leukemia (AML)

* Will temporarily delay clinical activities with APTO-253, a Phase 1 stage compound for AML

* Company does not intend to continue to provide preliminary results in future Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below